ClinicalTrials.gg

Program

AD-1161

A development code.

Its studies are mostly in Prostatic Hyperplasia, led by Yuhan.

Furthest: phase 1, since Jul 29, 20253 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Yuhan32 open or runningphase 1since Jul 29, 2025Jul 29, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2025First study: phase 1 study in Prostatic HyperplasiaFirst studyNCT07103278 · 44 enrolled · South Korea
  2. Jul 15, 20262 phase 1 studies in Prostatic HyperplasiaNCT07715305, NCT07722871

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722871Prostatic Hyperplasia · South Korea1Not yet recruitingOct 202644
NCT07715305Prostatic Hyperplasia · South Korea1Not yet recruitingAug 202644
NCT07103278Prostatic Hyperplasia · South Korea1CompletedMar 7, 202644

How it is read

Names in the registry

  • “AD-1161”, 3 entries

Codes read as this program: AD1161.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.